Last reviewed · How we verify
Tamoxifen + Aminoglutethimide
Tamoxifen acts as a selective estrogen receptor modulator (SERM) to inhibit estrogen's action in breast tissue, while aminoglutethimide inhibits the enzyme CYP11A1, which is involved in the synthesis of steroids, including estrogen.
Tamoxifen acts as a selective estrogen receptor modulator (SERM) to inhibit estrogen's action in breast tissue, while aminoglutethimide inhibits the enzyme CYP11A1, which is involved in the synthesis of steroids, including estrogen. Used for Adjuvant treatment of breast cancer in postmenopausal women with estrogen receptor-positive disease.
At a glance
| Generic name | Tamoxifen + Aminoglutethimide |
|---|---|
| Also known as | Nolvadex + Orimeten |
| Sponsor | Austrian Breast & Colorectal Cancer Study Group |
| Drug class | SERM and CYP11A1 inhibitor |
| Target | estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Tamoxifen's SERM activity blocks estrogen receptors in breast tissue, which can help slow or stop the growth of hormone receptor-positive breast cancer cells. Aminoglutethimide's inhibition of CYP11A1 reduces the production of estrogen, which can also slow the growth of hormone receptor-positive breast cancer cells.
Approved indications
- Adjuvant treatment of breast cancer in postmenopausal women with estrogen receptor-positive disease
Common side effects
- Hot flashes
- Vaginal discharge
- Nausea
- Vomiting
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: